Breakthroughs Announced at AACR Annual Meeting
The AACR Annual Meeting held in April in Chicago featured several research breakthroughs in ocular melanoma. Arguably the most exciting was a presentation from Dr. Jessica Hassell reviewing a phase III trial in metastatic uveal melanoma investigating the effect of tebentafusp, a drug that engages the T cells in the immune system, as a first-line treatment. Showing clear benefits versus other treatments such as immune checkpoint inhibitors, patients treated with tebentafusp had 36% median survival INCREASE. This is the first trial to show improvement in overall survival in metastatic uveal melanoma. Read more about the Annual Meeting updates >
Learn more about OMF's research funding initiatives and donate today to help fund the next eye cancer breakthrough!
Learn more about OMF's research funding initiatives and donate today to help fund the next eye cancer breakthrough!
Aura Biosciences Phase III Trial for Small Tumor Patients
Aura Biosciences is actively seeking newly diagnosed, small tumor OM patients for an exciting 100 patient Phase III trial to determine the safety and efficacy of their belzupacap sarotalocan (bel-sar) agent. Bel-sar is a novel drug that is injected into the eye where it selectively binds to OM cells. Then it's activated with light and proceeds to cause a physical disruption of the cell membrane leading to acute cellular necrosis, ie death of the tumor. This study is looking ONLY at patients with small lesions (primary indeterminate lesions (IL) or small choroidal melanoma (CM)) BEFORE they undergo plaque therapy.
You can learn more about the trial by emailing OMF or by visiting ClinicalTrials.gov.
You can learn more about the trial by emailing OMF or by visiting ClinicalTrials.gov.
